Kathryn Boor, PhD, was elected to our Board in June 2022. She currently serves as a member of the Compensation committee and Nominating and Corporate Governance committee.
Dr. Boor is the Dean of the Graduate School and Vice Provost for Graduate Education at Cornell University. Previously, Dr. Boor served as the Ronald P. Lynch Dean of the College of Agriculture and Life Sciences (CALS) at Cornell. She joined the Cornell Food Science department as assistant professor in 1994, became its first tenured female faculty member in 2000, and led as department chair from 2007-2010.
Dr. Boor serves on the Board of Directors for Seneca Foods Corporation, International Flavors and Fragrances, the United States-Israel Binational Agricultural Research and Development (BARD) Fund, as well as the Science Board for the US Food and Drug Administration. From 2011-2022, she served on the New York State Southern Tier Regional Economic Development Council. From 2014-2022, Dr. Boor served as a member of the board of directors and Vice President, Chair of Scientific Review Committee of the Foundation for Food and Agriculture Research (FFAR).
She earned her bachelor’s degree in food science from Cornell University, a master’s degree in food science from the University of Wisconsin and a Ph.D. in microbiology from the University of California, Davis.
What is Kathryn Jean Boor's net worth?
The estimated net worth of Kathryn Jean Boor is at least $721,711.20 as of December 5th, 2024. Dr. Boor owns 5,880 shares of Sarepta Therapeutics stock worth more than $721,711 as of December 26th. This net worth evaluation does not reflect any other assets that Dr. Boor may own. Learn More about Kathryn Jean Boor's net worth.
How do I contact Kathryn Jean Boor?
Has Kathryn Jean Boor been buying or selling shares of Sarepta Therapeutics?
Within the last three months, Kathryn Jean Boor has sold $205,399.80 in shares of Sarepta Therapeutics stock. Most recently, Kathryn Jean Boor sold 1,636 shares of the business's stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a transaction totalling $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares of the company's stock, valued at $738,234. Learn More on Kathryn Jean Boor's trading history.
Who are Sarepta Therapeutics' active insiders?
Sarepta Therapeutics' insider roster includes Bilal Arif (EVP, Chief Technical Operations Officer), Richard Barry (Director), M. Behrens (Director), Kathryn Boor (Director), Joseph Bratica (Insider), Ryan Brown (EVP), Michael Chambers (Director), Ian Estepan (EVP, Chief Financial Officer), David Howton (EVP), Douglas Ingram (CEO), Stephen Mayo (Director), Dallan Murray (EVP, Chief Customer Officer), Louise Rodino-Klapac (Insider), and Hans Wigzell (Director). Learn More on Sarepta Therapeutics' active insiders.
Are insiders buying or selling shares of Sarepta Therapeutics?
In the last twelve months, Sarepta Therapeutics insiders bought shares 1 times. They purchased a total of 37,038 shares worth more than $4,955,684.40. In the last twelve months, insiders at the biotechnology company sold shares 11 times. They sold a total of 90,668 shares worth more than $13,164,125.22. The most recent insider tranaction occured on December, 12th when Director Hans Lennart Rudolf Wigzell sold 10,500 shares worth more than $1,310,820.00. Insiders at Sarepta Therapeutics own 7.7% of the company.
Learn More about insider trades at Sarepta Therapeutics. Information on this page was last updated on 12/12/2024.
